vs
Alexander & Baldwin, Inc.（ALEX）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Alexander & Baldwin, Inc.的1.5倍（$75.5M vs $51.0M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -18.4%），Alexander & Baldwin, Inc.自由现金流更多（$27.3M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -8.7%）
亚历山大-鲍德温公司是一家美国企业，曾是夏威夷领地时期五大财团之一，也是五大财团中最晚停止甘蔗种植的企业。目前公司主营房地产开发、土地运营以及建材与建筑业务，截至2020年，该公司是夏威夷最大的私人土地持有者之一，在当地拥有超2.8万英亩土地，运营着36处收益性物业。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
ALEX vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.5倍
$51.0M
营收增速更快
PBYI
高出46.1%
-18.4%
自由现金流更多
ALEX
多$12.9M
$14.4M
两年增速更快
PBYI
近两年复合增速
-8.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $51.0M | $75.5M |
| 净利润 | $3.8M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 17.1% | 22.7% |
| 净利率 | 7.4% | — |
| 营收同比 | -18.4% | 27.7% |
| 净利润同比 | -69.7% | — |
| 每股收益（稀释后） | $0.05 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALEXPBYI
| Q4 25 | $51.0M | $75.5M | ||
| Q3 25 | $50.2M | $54.5M | ||
| Q2 25 | $51.7M | $52.4M | ||
| Q1 25 | $53.7M | $46.0M | ||
| Q4 24 | $62.4M | $59.1M | ||
| Q3 24 | $61.9M | $80.5M | ||
| Q2 24 | $51.0M | $47.1M | ||
| Q1 24 | $61.2M | $43.8M |
净利润ALEXPBYI
| Q4 25 | $3.8M | — | ||
| Q3 25 | $14.3M | $8.8M | ||
| Q2 25 | $25.1M | $5.9M | ||
| Q1 25 | $21.4M | $3.0M | ||
| Q4 24 | $12.4M | — | ||
| Q3 24 | $19.0M | $20.3M | ||
| Q2 24 | $9.1M | $-4.5M | ||
| Q1 24 | $20.0M | $-4.8M |
毛利率ALEXPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率ALEXPBYI
| Q4 25 | 17.1% | 22.7% | ||
| Q3 25 | 38.2% | 17.6% | ||
| Q2 25 | 54.4% | 12.7% | ||
| Q1 25 | 44.6% | 8.7% | ||
| Q4 24 | 28.3% | 22.6% | ||
| Q3 24 | 35.6% | 27.4% | ||
| Q2 24 | 31.8% | -4.6% | ||
| Q1 24 | 38.9% | -5.3% |
净利率ALEXPBYI
| Q4 25 | 7.4% | — | ||
| Q3 25 | 28.5% | 16.2% | ||
| Q2 25 | 48.6% | 11.2% | ||
| Q1 25 | 39.9% | 6.5% | ||
| Q4 24 | 19.9% | — | ||
| Q3 24 | 30.7% | 25.2% | ||
| Q2 24 | 17.8% | -9.6% | ||
| Q1 24 | 32.6% | -11.0% |
每股收益（稀释后）ALEXPBYI
| Q4 25 | $0.05 | $0.26 | ||
| Q3 25 | $0.20 | $0.17 | ||
| Q2 25 | $0.35 | $0.12 | ||
| Q1 25 | $0.29 | $0.06 | ||
| Q4 24 | $0.16 | $0.40 | ||
| Q3 24 | $0.26 | $0.41 | ||
| Q2 24 | $0.13 | $-0.09 | ||
| Q1 24 | $0.28 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.3M | $97.5M |
| 总债务越低越好 | $491.6M | $22.7M |
| 股东权益账面价值 | $987.2M | $130.3M |
| 总资产 | $1.7B | $216.3M |
| 负债/权益比越低杠杆越低 | 0.50× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资ALEXPBYI
| Q4 25 | $11.3M | $97.5M | ||
| Q3 25 | $17.3M | $94.4M | ||
| Q2 25 | $8.6M | $96.0M | ||
| Q1 25 | $16.9M | $93.2M | ||
| Q4 24 | $33.4M | $101.0M | ||
| Q3 24 | $17.9M | $96.7M | ||
| Q2 24 | $29.5M | $96.8M | ||
| Q1 24 | $15.7M | $107.2M |
总债务ALEXPBYI
| Q4 25 | $491.6M | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | $474.8M | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益ALEXPBYI
| Q4 25 | $987.2M | $130.3M | ||
| Q3 25 | $1.0B | $115.3M | ||
| Q2 25 | $1.0B | $104.7M | ||
| Q1 25 | $1.0B | $97.1M | ||
| Q4 24 | $1.0B | $92.1M | ||
| Q3 24 | $998.2M | $71.1M | ||
| Q2 24 | $1.0B | $48.5M | ||
| Q1 24 | $1.0B | $51.0M |
总资产ALEXPBYI
| Q4 25 | $1.7B | $216.3M | ||
| Q3 25 | $1.7B | $202.9M | ||
| Q2 25 | $1.6B | $194.9M | ||
| Q1 25 | $1.6B | $196.2M | ||
| Q4 24 | $1.7B | $213.3M | ||
| Q3 24 | $1.7B | $220.7M | ||
| Q2 24 | $1.6B | $205.0M | ||
| Q1 24 | $1.6B | $214.1M |
负债/权益比ALEXPBYI
| Q4 25 | 0.50× | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 0.47× | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $79.5M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $27.3M | $14.4M |
| 自由现金流率自由现金流/营收 | 53.5% | 19.1% |
| 资本支出强度资本支出/营收 | 102.4% | 0.0% |
| 现金转化率经营现金流/净利润 | 21.06× | — |
| 过去12个月自由现金流最近4个季度 | $57.2M | $41.7M |
8季度趋势，按日历期对齐
经营现金流ALEXPBYI
| Q4 25 | $79.5M | $14.4M | ||
| Q3 25 | $24.5M | $9.7M | ||
| Q2 25 | $16.5M | $14.1M | ||
| Q1 25 | $26.0M | $3.6M | ||
| Q4 24 | $98.0M | $15.6M | ||
| Q3 24 | $35.3M | $11.0M | ||
| Q2 24 | $22.3M | $1.0M | ||
| Q1 24 | $16.1M | $11.2M |
自由现金流ALEXPBYI
| Q4 25 | $27.3M | $14.4M | ||
| Q3 25 | $-3.7M | $9.7M | ||
| Q2 25 | $11.8M | $14.1M | ||
| Q1 25 | $21.8M | $3.6M | ||
| Q4 24 | $77.0M | $15.6M | ||
| Q3 24 | $31.4M | $11.0M | ||
| Q2 24 | $18.0M | $1.0M | ||
| Q1 24 | $12.3M | — |
自由现金流率ALEXPBYI
| Q4 25 | 53.5% | 19.1% | ||
| Q3 25 | -7.4% | 17.7% | ||
| Q2 25 | 22.8% | 26.8% | ||
| Q1 25 | 40.6% | 7.7% | ||
| Q4 24 | 123.4% | 26.4% | ||
| Q3 24 | 50.8% | 13.7% | ||
| Q2 24 | 35.3% | 2.1% | ||
| Q1 24 | 20.1% | — |
资本支出强度ALEXPBYI
| Q4 25 | 102.4% | 0.0% | ||
| Q3 25 | 56.1% | 0.0% | ||
| Q2 25 | 9.1% | 0.0% | ||
| Q1 25 | 7.8% | 0.1% | ||
| Q4 24 | 33.5% | 0.0% | ||
| Q3 24 | 6.2% | 0.0% | ||
| Q2 24 | 8.4% | 0.0% | ||
| Q1 24 | 6.1% | 0.0% |
现金转化率ALEXPBYI
| Q4 25 | 21.06× | — | ||
| Q3 25 | 1.71× | 1.10× | ||
| Q2 25 | 0.66× | 2.41× | ||
| Q1 25 | 1.21× | 1.21× | ||
| Q4 24 | 7.88× | — | ||
| Q3 24 | 1.86× | 0.54× | ||
| Q2 24 | 2.45× | — | ||
| Q1 24 | 0.80× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
